Literature DB >> 10779444

Differential expression and regulation of GTPases (RhoA and Rac2) and GDIs (LyGDI and RhoGDI) in neutrophils from patients with severe congenital neutropenia.

B Kasper1, N Tidow, D Grothues, K Welte.   

Abstract

Severe congenital neutropenia (SCN) or Kostmann syndrome is a disorder of myelopoiesis characterized by a maturation arrest at the stage of promyelocytes or myelocytes in bone marrow and absolute neutrophil counts less than 200/microL in peripheral blood. Treatment of these patients with granulocyte colony-stimulating factor (G-CSF) leads to a significant increase in circulating neutrophils and a reduction in infection-related events in more than 95% of the patients. To date, little is known regarding the underlying pathomechanism of SCN. G-CSF-induced neutrophils of patients with SCN are functionally defective (eg, chemotaxis, superoxide anion generation, Ca(++ )mobilization). Two guanosine triphosphatases (GTPases), Rac2 and RhoA, were described to be involved in many neutrophil functions. The expression of these GTPases and their regulation in patients' neutrophils were of interest. This study determined that the guanosine diphosphate (GDP)-dissociation inhibitor RhoGDI is overexpressed at the protein level in patients' neutrophils and that overexpression is a result of G-CSF treatment. RhoA and LyGDI are expressed at similar levels, whereas Rac2 shows a decreased expression. In addition, association of Rac2 and RhoGDI or LyGDI is abrogated or not detectable based on the low Rac2 expression in patients' neutrophils. (Blood. 2000;95:2947-2953)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779444

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  Crossroads of PI3K and Rac pathways.

Authors:  Carlo C Campa; Elisa Ciraolo; Alessandra Ghigo; Giulia Germena; Emilio Hirsch
Journal:  Small GTPases       Date:  2015-05-05

2.  Loss of RhoGDI is a novel independent prognostic factor in hepatocellular carcinoma.

Authors:  Weidong Li; Hui Wang; Xuejun Jin; Liang Zhao
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

3.  Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics.

Authors:  Elias J Sayour; Luis Sanchez-Perez; Catherine Flores; Duane A Mitchell
Journal:  J Immunother Cancer       Date:  2015-04-21       Impact factor: 13.751

4.  Active RHOA favors retention of human hematopoietic stem/progenitor cells in their niche.

Authors:  Bithiah Grace Jaganathan; Fernando Anjos-Afonso; Atul Kumar; Dominique Bonnet
Journal:  J Biomed Sci       Date:  2013-09-11       Impact factor: 8.410

5.  NF-κB p65 Overexpression Promotes Bladder Cancer Cell Migration via FBW7-Mediated Degradation of RhoGDIα Protein.

Authors:  Junlan Zhu; Yang Li; Caiyi Chen; Jiugao Ma; Wenrui Sun; Zhongxian Tian; Jingxia Li; Jiheng Xu; Claire S Liu; Dongyun Zhang; Chuanshu Huang; Haishan Huang
Journal:  Neoplasia       Date:  2017-08-01       Impact factor: 5.715

6.  Expression of RHOGTPase regulators in human myometrium.

Authors:  Margaret O'Brien; David Flynn; Brian Mullins; John J Morrison; Terry J Smith
Journal:  Reprod Biol Endocrinol       Date:  2008-01-11       Impact factor: 5.211

7.  RhoGDIbeta-induced hypertrophic growth in H9c2 cells is negatively regulated by ZAK.

Authors:  Chih-Yang Huang; Li-Chiu Yang; Kuan-Yu Liu; Pao-Hsin Liao; Janet Ing-Yuh Chou; Ming-Yung Chou; Wei-Wen Lin; Jaw-Ji Yang
Journal:  J Biomed Sci       Date:  2009-01-22       Impact factor: 8.410

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.